Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Molecular Advances in Dry Eye Syndrome
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Advances in Dry Eye Syndrome

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1716

Special Issue Editors

Dr. Maria Jesus Giráldez-Fernández

E-Mail Website
Guest Editor
GI-2092—Optometry, Department of Applied Physics (Optometry Area), Universidade de Santiago de Compostela, Campus Vida s/n, Santiago de Compostela, Spain
Interests: dry eye disease; ocular surface; contact lens; tear substitutes
Dr. Anxo Fernández Ferreiro

E-Mail Website
Guest Editor
Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
Interests: ocular drug delivery; ocular pharmacokinetic; drug development; pharmacogenetics; clinical and translational research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Dry eye disease (DED) is a common ocular surface disease affecting a significant percentage of the population. Caused by tear film homeostasis disruption, DED is characterized by dryness, inflammation, discomfort, and visual disturbances. This condition greatly affects the quality of life of patients, and can potentially lead to permanent vision loss.

The purpose of this Special Issue is to report recent molecular advances in DED to assist in developing a better knowledge of DED-related pathophysiological mechanisms, diagnostic methods, and therapeutic approaches.

Potential topics include, but are not limited to, both immune and adaptive immune responses, ocular surface signs and symptoms, diagnostic methods, new pharmacological treatments, and specialized drug delivery systems.

Dr. Maria Jesus Giráldez-Fernández
Dr. Anxo Fernández Ferreiro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dry eye disease
  • tear film osmolarity
  • tear film
  • artificial tear substitutes
  • biological tear substitutes
  • tear fluid biomarkers
  • tear film lipid layer
  • meibomian gland dysfunction
  • evaporative dry eye
  • aqueous deficiency dry eye
  • ocular surface inflammation
  • cytokines
  • histological analysis
  • pharmacological treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1125 KiB  
Article
Clinical Effectiveness, Safety, and Compliance of Two Compounded Formulations of Tacrolimus Eye Drops: An Open-Label, Sequential Prospective Study
by María Puente-Iglesias, Andrea Cuartero-Martínez, Rosario Touriño-Peralba, María Teresa Rodríguez-Ares, María Jesús Giráldez, Eva Yebra-Pimentel, Laura García-Quintanilla, Xurxo García-Otero, Miguel González-Barcia, Irene Zarra-Ferro, Francisco J. Otero-Espinar, Anxo Fernández-Ferreiro and Ana Castro-Balado
Int. J. Mol. Sci. 2024, 25(18), 9847; https://doi.org/10.3390/ijms25189847 - 12 Sep 2024
Viewed by 368
Abstract
Ophthalmic tacrolimus compounded formulations are usually made from the commercial intravenous presentation, which contains ethanol as a solubilizer due to the low solubility of tacrolimus. The use of cyclodextrins is presented as an alternative to ethanol, an ocular irritant excipient, to avoid its [...] Read more.
Ophthalmic tacrolimus compounded formulations are usually made from the commercial intravenous presentation, which contains ethanol as a solubilizer due to the low solubility of tacrolimus. The use of cyclodextrins is presented as an alternative to ethanol, an ocular irritant excipient, to avoid its long-term irritant effects. Open-label, sequential, prospective study to compare effectiveness, safety, and adherence of a new formulation of 0.015% tacrolimus with cyclodextrins (TCD) versus 0.03% tacrolimus with ethanol (TE). The ocular evaluation was assessed by ocular signs, corneal staining, subjective questionnaires as Visual Function Questionnaire (VFQ-25) and Visual Analogue Scale (VAS) of symptoms, lacrimal stability, ocular redness, and intraocular pressure. Compliance was assessed by VAS of adherence and empirically (difference between theoretical and actual consumption). Clinical ocular signs and corneal staining score remained stable for most patients 3 months after switching formulations. The TCD formulation did not modify the tear stability and intraocular pressure of the treated patients compared to the TE formulation. TCD eye drops significantly decreased the subjective pain values on VFQ-25 scale and burning sensation on the VAS symptom scale in comparison to TE formulation after 3 months after the change to TCD formulation. The novel tacrolimus in cyclodextrins formulation is a promising alternative for treating inflammatory ocular pathologies refractory to first-line treatments. Full article
(This article belongs to the Special Issue Molecular Advances in Dry Eye Syndrome)
►▼ Show Figures

Figure 1

17 pages, 11790 KiB  
Article
Meibum Lipidomic Analysis in Evaporative Dry Eye Subjects
by Jacobo Garcia-Queiruga, Hugo Pena-Verdeal, Belen Sabucedo-Villamarin, Monica Paz-Tarrio, Esteban Guitian-Fernandez, Carlos Garcia-Resua, Eva Yebra-Pimentel and Maria J. Giraldez
Int. J. Mol. Sci. 2024, 25(9), 4782; https://doi.org/10.3390/ijms25094782 - 27 Apr 2024
Viewed by 1040
Abstract
Meibomian Glands (MG) are sebaceous glands responsible for the production of meibum, the main component of the Tear Film Lipid Layer (TFLL). The TFLL facilitates the spread of the tear film over the ocular surface, provides stability and reduces tear evaporation. Alterations in [...] Read more.
Meibomian Glands (MG) are sebaceous glands responsible for the production of meibum, the main component of the Tear Film Lipid Layer (TFLL). The TFLL facilitates the spread of the tear film over the ocular surface, provides stability and reduces tear evaporation. Alterations in meibum composition lead to different ocular alterations like Meibomian Gland Dysfunction (MGD) and subsequent Evaporative Dry Eye (EDE). The aim of the present study was to investigate the composition and abundance of meibum lipids and their relationship with eyelid margin abnormalities, lipid layer patterns and MG status. The study utilizes a lipidomic approach to identify and quantify lipids in meibum samples using an Elute UHPLC system. This system considered all four dimensions (mass/charge, retention time, ion mobility and intensity) to provide the accurate identification of lipid species. Samples were categorized as healthy or low/no signs of alteration (group 1) or severe signs of alteration or EDE/MGD (group 2). The current investigation found differences in Variable Importance in Projection lipid abundance between both groups for the MGD signs studied. Changes in meibum composition occur and are related to higher scores in eyelid margin hyperaemia, eyelid margin irregularity, MG orifice plugging, MG loss and lipid layer pattern. Full article
(This article belongs to the Special Issue Molecular Advances in Dry Eye Syndrome)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop